MedTrace Logo

The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus

NCT04633733 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-11-18

No results posted yet for this study

Summary

This study aims to evaluate the pharmacokinetic interaction between HL237 and tacrolimus in healthy male subjects.

Conditions

  • Healthy Male Volunteers

Interventions

DRUG

HL237 tablet

HL237 400mg will be administered orally twice a day.

DRUG

tacrolimus capsule

tacrolimus 5mg will be administered orally once a day.

Sponsors & Collaborators

  • Hanlim Pharm. Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-22
Primary Completion
2020-09-24
Completion
2021-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04633733 on ClinicalTrials.gov